Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone612-379-8854
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$642.99 million
Profitability
Miscellaneous
Employees2,000
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Wednesday, May 1st. Stockholders of record on Friday, May 10th will be given a dividend of $0.32 per share on Friday, May 24th. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, May 9th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) posted its earnings results on Tuesday, April, 30th. The biotechnology company reported $1.21 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.94 by $0.27. The biotechnology company earned $184.86 million during the quarter, compared to the consensus estimate of $183.92 million. BIO-TECHNE had a return on equity of 13.53% and a net margin of 17.15%. The company's revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 EPS. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
8 equities research analysts have issued twelve-month price objectives for BIO-TECHNE's stock. Their forecasts range from $165.00 to $230.00. On average, they expect BIO-TECHNE's share price to reach $188.1250 in the next year. This suggests that the stock has a possible downside of 5.2%. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Has BIO-TECHNE been receiving favorable news coverage?
Press coverage about TECH stock has been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIO-TECHNE earned a news impact score of -2.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of BIO-TECHNE own?
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
- Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
- Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
- Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
- Mr. Gerry Andros, VP of Sales and Marketing
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.13%), Wellington Management Group LLP (4.08%), Janus Henderson Group PLC (3.72%), Neuberger Berman Group LLC (3.67%), Mairs & Power INC (3.05%) and Jackson Square Partners LLC (2.33%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which institutional investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, First Trust Advisors LP, Hsbc Holdings PLC, Goldman Sachs Group Inc., BTIM Corp., BNP Paribas Arbitrage SA and Riverbridge Partners LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, James Hippel and John L Higgins. View Insider Buying and Selling for BIO-TECHNE.
Which institutional investors are buying BIO-TECHNE stock?
TECH stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ellis Investment Partners LLC, SEI Investments Co, Sandler Capital Management, Bradley Foster & Sargent Inc. CT, 12 West Capital Management LP, Jackson Square Partners LLC and OppenheimerFunds Inc.. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $198.45.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $7.52 billion and generates $642.99 million in revenue each year. The biotechnology company earns $126.15 million in net income (profit) each year or $4.07 on an earnings per share basis. BIO-TECHNE employs 2,000 workers across the globe.
What is BIO-TECHNE's official website?
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
